CN114736186A - Method for synthesizing vilanterol intermediate from tert-butyl carbamate - Google Patents

Method for synthesizing vilanterol intermediate from tert-butyl carbamate Download PDF

Info

Publication number
CN114736186A
CN114736186A CN202210524284.9A CN202210524284A CN114736186A CN 114736186 A CN114736186 A CN 114736186A CN 202210524284 A CN202210524284 A CN 202210524284A CN 114736186 A CN114736186 A CN 114736186A
Authority
CN
China
Prior art keywords
tert
butyl carbamate
vilanterol
synthesizing
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210524284.9A
Other languages
Chinese (zh)
Other versions
CN114736186B (en
Inventor
张启龙
许坤
张文成
王红磊
惠爱玲
汪崇文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Dexinjia Biopharm Co ltd
Original Assignee
Anhui Dexinjia Biopharm Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Dexinjia Biopharm Co ltd filed Critical Anhui Dexinjia Biopharm Co ltd
Priority to CN202210524284.9A priority Critical patent/CN114736186B/en
Publication of CN114736186A publication Critical patent/CN114736186A/en
Application granted granted Critical
Publication of CN114736186B publication Critical patent/CN114736186B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/081,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a method for synthesizing a vilanterol intermediate from tert-butyl carbamate, belonging to the field of drug synthesis. The method takes 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin as a raw material to perform substitution reaction with tert-butyl carbamate to obtain N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) tert-butyl carbamate. The invention provides a synthetic method of a vilanterol intermediate, which uses cheap and easily available tert-butyl carbamate as a raw material, has mild synthetic reaction conditions and simple operation, shortens the synthetic route of vilanterol synthesized by the intermediate, reduces the production cost, and is suitable for industrial production.

Description

Method for synthesizing vilanterol intermediate from tert-butyl carbamate
Technical Field
The invention belongs to the field of drug synthesis, and relates to a method for synthesizing a vilanterol intermediate from tert-butyl carbamate.
Background
Vilanterol trihydronate is a long-acting beta developed by Kulanin Schker (GSK)2A receptor agonist. Its compound preparation with furoic acid fluticasone and umeclidinium bromideThe compound preparation is approved by FDA in 5 months and 12 months in 2013 respectively, and is used for treating obstructive pulmonary disease and asthma. Wherein, the N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamic acid tert-butyl ester is a key intermediate for synthesizing vilanterol, CAS: 452339-71-8, formula: c17H23NO5Molecular weight: 321.37. the structural formulae of vilanterol and tert-butyl N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamate are shown below:
Figure BDA0003643451650000011
currently, there are two main routes for the synthesis of tert-butyl N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamate.
Route one (WO2003024439, CN 107188813): 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin is taken as a raw material to carry out substitution reaction with bis (tert-butyloxycarbonyl) amine under the action of cesium carbonate, and then one Boc protecting group on N is selectively removed under the action of trifluoroacetic acid to obtain N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamic acid tert-butyl ester.
Figure BDA0003643451650000012
The route is an original research route developed by Kulansu Schke pharmaceutical company, the total rate of two steps is only 48.6%, bis (tert-butyloxycarbonyl) amine is expensive, and trifluoroacetic acid in the second step reaction can easily remove two Bocs on N, so that the selectivity is poor, and the product is difficult to purify.
Route two (CN105646285, guangdong chemical industry 2018,45 (05)): 6-Bromoacetyl-2, 2-dimethyl-4H-benzo [1,3]]Converting bromine into amino group by using dioxin as raw material through a Delbin reaction or a Staudinger reaction, and then reacting with Boc2The N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamic acid tert-butyl ester is obtained by O reaction, and the specific synthesis process is as follows:
Figure BDA0003643451650000021
the reaction route avoids using expensive bis (tert-butyloxycarbonyl) amine and simultaneously avoids the problem of poor selectivity of trifluoroacetic acid for removing Boc protecting group, but the reaction step is too long, so that the total yield is low.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a method for synthesizing a vilanterol intermediate from tert-butyl carbamate, wherein the tert-butyl carbamate can be prepared by the reaction of tert-butyl alcohol and a benzene solution of trifluoroacetic acid in sodium cyanate, and is a large amount of chemical raw materials, simple in synthesis process, low in price and easy to obtain. The invention takes 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin as a raw material and tert-butyl carbamate, and adds strong base into a solvent at low temperature to carry out substitution reaction, and the technical scheme is as follows:
Figure BDA0003643451650000022
the solvent is one of acetonitrile, tetrahydrofuran, DMF, 1, 4-dioxane and N-methyl pyrrolidone, and tetrahydrofuran is preferred; the alkali is one of sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydride and lithium diisopropylamide, and preferably lithium diisopropylamide; the molar ratio of the 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin serving as a raw material to the tert-butyl carbamate is 1: 1.1; the reaction temperature is-5-0 ℃.
The invention has the beneficial effects that:
(1) the invention can obtain the vilanterol intermediate N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamic acid tert-butyl ester by only one-step reaction, and the reaction yield is 83 percent.
(2) Avoids using expensive bis (tert-butyloxycarbonyl) amine and simultaneously avoids the problem of poor selectivity of trifluoroacetic acid for removing Boc protecting group.
(3) The invention shortens the synthetic route, has simple post-treatment, reduces the production cost and is suitable for industrial production.
Detailed Description
Example 1:
adding tert-butyl carbamate (225g, 1.1eq) into a 5L three-neck flask at room temperature, adding 500mL of tetrahydrofuran, stirring for dissolving, turning the system to-5-0 ℃, slowly and dropwise adding LDA (960mL, 2mol/L, 1.1eq) solution, keeping the temperature and stirring for 0.5H after the addition is finished, then slowly adding a solution prepared from 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin (500g, 1.0eq) and 1L of tetrahydrofuran into the reaction system, and keeping the temperature and reacting for 2H after the addition is finished. After the neutralization reaction was completed, the reaction solution was concentrated, then saturated sodium bicarbonate solution (2L) and ethyl acetate (2L) were added, the residue was stirred and dispersed, the organic layer was separated, washed with water (2L) and saturated brine (2L), and then dried over anhydrous sodium sulfate, magnesium sulfate was removed by filtration, the solvent was removed by vacuum concentration, isopropyl ether (1L) was added, crystallized by stirring at room temperature, and filtered to obtain 467g of white powdery solid, yield 83%, purity 99.1%.
Example 2:
adding tert-butyl carbamate (225g, 1.1eq) into a 5L three-neck flask at room temperature, adding tetrahydrofuran (500mL) and stirring for dissolving, bringing the system to-5-0 ℃, slowly adding potassium tert-butoxide (217g, 1.1eq) solution, keeping the temperature and stirring for 0.5H after the addition is finished, then slowly adding a solution prepared from 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin (500g, 1.0eq) and 1L tetrahydrofuran into the reaction system, and keeping the temperature and reacting for 2H after the addition is finished. After the reaction was completed, the reaction solution was concentrated, then saturated sodium bicarbonate solution (2L) and ethyl acetate (2L) were added, the residue was dispersed with stirring, the liquid was separated, the organic layer was washed with water (2L) and saturated brine (2L), and then dried over anhydrous sodium sulfate, magnesium sulfate was removed by filtration, the solvent was removed by vacuum concentration, isopropyl ether (1L) was added, crystallization was performed with stirring at room temperature, and the filtrate was filtered to obtain 456g of a white powdery solid with a yield of 81% and a purity of 99.1%.
Example 3:
adding tert-butyl carbamate (225g, 1.1eq) into a 5L three-neck flask at room temperature, adding tetrahydrofuran (500mL) and stirring for dissolving, slowly adding potassium tert-butoxide (217g, 1.1eq) solution at room temperature, stirring for 0.5H after the addition is finished, then slowly dropwise adding a solution prepared from 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin (500g, 1.0eq) and 1L tetrahydrofuran into a reaction system, and preserving heat for 2H after the addition is finished. After the reaction was completed, the reaction solution was concentrated, then saturated sodium bicarbonate solution (2L) and ethyl acetate (2L) were added, the residue was dispersed with stirring, the liquid was separated, the organic layer was washed with water (2L) and saturated brine (2L), and then dried over anhydrous sodium sulfate, magnesium sulfate was removed by filtration, the solvent was removed by vacuum concentration, isopropyl ether (1L) was added, crystallization was performed with stirring at room temperature, and filtration gave 433g of white powdery solid, 77% yield and 97.3% purity.
Example 4:
adding tert-butyl carbamate (205g, 1.0eq) into a 5L three-neck flask at room temperature, adding tetrahydrofuran (500mL), stirring for dissolving, slowly adding a potassium tert-butoxide (196g, 1.0eq) solution at room temperature, stirring for 0.5H after adding, then slowly dropwise adding a solution prepared from 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin (500g, 1.0eq) and 1L tetrahydrofuran into a reaction system, and preserving heat for reacting for 2H after adding. After the neutralization reaction was completed, the reaction solution was concentrated, then a saturated sodium bicarbonate solution (2L) and ethyl acetate (2L) were added, the residue was stirred and dispersed, liquid separation was performed, the organic layer was washed with water (2L) and a saturated saline solution (2L), and then dried with anhydrous sodium sulfate, magnesium sulfate was removed by filtration, the solvent was removed by vacuum concentration, isopropyl ether (1L) was added, crystallization was performed under stirring at room temperature, and a white powdery solid was obtained by filtration in a yield of 72% and a purity of 98.7%.
Example 5:
A5L three-necked flask was charged with cesium carbonate (66.54g), acetonitrile (600mL), 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxine (58.4g) and bis (t-butoxycarbonyl) amine (44.56g), reacted at room temperature for 24 hours with mechanical stirring, diluted with water (1L), extracted with diethyl ether (1L), and the organic layer was washed with brine (1L), dried, concentrated to give a yellow solid, and recrystallized from diethyl ether to give di- (t-butyl) 2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyliminodicarbonic acid as a white crystalline solid in 24.4g at 28% yield.
Trifluoroacetic acid (10.2mL) was added to a stirred solution of di- (tert-butyl) 2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyliminodicarbonate (46.37g) and dichloromethane (500mL) at 20 ℃ and stirred for 4 hours. Aqueous sodium hydroxide (0.5M, 400mL) was added to the reaction mixture, stirred for half an hour, and the solution was separated. The organic layer was washed with water (500mL), dried, concentrated, and recrystallized from ether to give 15.15g of tert-butyl N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) carbamate in 43% yield.
Although the present invention has been described with reference to the specific embodiments, it should be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.

Claims (5)

1. A method for synthesizing a vilanterol intermediate from tert-butyl carbamate uses 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxin as a raw material and tert-butyl carbamate, and adds strong base at low temperature in a solvent to carry out substitution reaction to obtain the vilanterol intermediate N- (2- (2, 2-dimethyl-4H-1, 3-benzodioxin-6-yl) -2-oxoethyl) tert-butyl carbamate, wherein the specific synthesis process is as follows:
Figure FDA0003643451640000011
2. the method for synthesizing vilanterol intermediate from tert-butyl carbamate according to claim 1, wherein the solvent is one of acetonitrile, tetrahydrofuran, DMF, 1, 4-dioxane, N-methylpyrrolidone.
3. The method for synthesizing vilanterol intermediate from tert-butyl carbamate according to claim 1, wherein the base is one of sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide.
4. The method for synthesizing vilanterol intermediate from tert-butyl carbamate according to claim 1, wherein the molar ratio of 6-bromoacetyl-2, 2-dimethyl-4H-benzo [1,3] dioxine to tert-butyl carbamate is 1: 1.1.
5. The method for synthesizing vilanterol intermediate from tert-butyl carbamate according to claim 1, wherein the reaction temperature is-5 to 0 ℃.
CN202210524284.9A 2022-05-13 2022-05-13 Method for synthesizing Violet Luo Zhongjian body from tert-butyl carbamate Active CN114736186B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210524284.9A CN114736186B (en) 2022-05-13 2022-05-13 Method for synthesizing Violet Luo Zhongjian body from tert-butyl carbamate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210524284.9A CN114736186B (en) 2022-05-13 2022-05-13 Method for synthesizing Violet Luo Zhongjian body from tert-butyl carbamate

Publications (2)

Publication Number Publication Date
CN114736186A true CN114736186A (en) 2022-07-12
CN114736186B CN114736186B (en) 2023-08-08

Family

ID=82285146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210524284.9A Active CN114736186B (en) 2022-05-13 2022-05-13 Method for synthesizing Violet Luo Zhongjian body from tert-butyl carbamate

Country Status (1)

Country Link
CN (1) CN114736186B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646285A (en) * 2014-12-02 2016-06-08 上海医药工业研究院 Vilanterol intermediate, preparation method and application thereof
CN107188813A (en) * 2016-03-14 2017-09-22 益方生物科技(上海)有限公司 Phenethanolamine derivative and its production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646285A (en) * 2014-12-02 2016-06-08 上海医药工业研究院 Vilanterol intermediate, preparation method and application thereof
CN107188813A (en) * 2016-03-14 2017-09-22 益方生物科技(上海)有限公司 Phenethanolamine derivative and its production and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALHANOUF Z. ALJAHDALI,ET AL.: "Asymmetric synthesis of 7-aza-phomopsolide E and its C-4 epimer", 《TETRAHEDRON》 *
陈雨等: "维兰特罗三苯乙酸盐合成路线图解", 《中国医药工业杂志》 *

Also Published As

Publication number Publication date
CN114736186B (en) 2023-08-08

Similar Documents

Publication Publication Date Title
EP0529842B1 (en) Production of fluoxetine and new intermediates
KR20110026412A (en) Method for producing an intermediate product of dabigatran etexilate
CN106459150B (en) Method for producing synthetic pentapeptide
EP2027083A1 (en) Method of preparing chiral cyclic beta-aminocarboxamides
CN106699604B (en) One seed sand library is than bent and its intermediate preparation method
CN110551144B (en) Preparation method of amoxicillin
CN108084145B (en) Ticagrelor intermediate and preparation method thereof
KR101269491B1 (en) Preparation method for entecavir
CN111527067B (en) Process for the preparation of 1- [5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethylamine monofumarate
CN114736186A (en) Method for synthesizing vilanterol intermediate from tert-butyl carbamate
EP3498695A1 (en) Method for synthesizing 3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxylic acid, and intermediates thereof
CN112920053B (en) Preparation method of chiral alpha-methyl aromatic ethylamine
CN109574860B (en) Method for preparing vilanterol
KR101327866B1 (en) Improved process for preparing Mitiglinide calcium salt
JP2019534299A (en) Process for producing (S) -N1- (2-aminoethyl) -3- (4-alkoxyphenyl) propane-1,2-diamine trihydrochloride
CN106946724A (en) The synthetic method of the benzyl malonic acid mono ethyl ester of 2 acetylamino of monoamine base inhibitor class intermediate 2
CN111423342A (en) Preparation method for co-production of N-methyl-2-fluoroaniline and crystalline sulfanilamide
CN109265385A (en) A kind of synthesis technology of chiral catalyst
CN111233921A (en) Novel compound and method for synthesizing fosfomycin impurity D by using same
CN103044434A (en) Preparation method for chiral pentabasic bicyclic guanidine based on aziridine
CN116082361B (en) Method for preparing Marbalo Sha Wei intermediate and Marbalo Sha Wei
CN115181077B (en) Synthesis method of vortioxetine with low impurity content
CN112321599B (en) Synthesis method of drug intermediate 7-oxo-2-azaspiro [3.5] nonane
CN115872923B (en) Compound and preparation method thereof
CN109369618B (en) Method for preparing 2-chloro-5- ((2- (nitromethylene) imidazoline-1-yl) methyl) pyridine in one pot

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant